Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to confirm that the investigational medication, plecanatide, is safe and effective in treating chronic idiopathic constipation.


Clinical Trial Description

This is a national, randomized, 12-week, double-blind, placebo-controlled, study in approximately 1350 adult male and female patients with CIC comparing 2 doses of plecanatide to placebo. The study will be conducted at approximately 180 clinical study sites in the United States. The primary objective of the study is to evaluate the efficacy and safety of 3.0 and 6.0 mg of plecanatide administered once daily (QD) for 12 weeks in a population of patients with CIC. The study population will include only patients without other causes of constipation or other chronic conditions that could interfere with study assessments. Patients may not take laxatives (with the exception of the study-provided rescue medication, bisacodyl 5mg tablets), or a number of prohibited drugs that are known to cause constipation or diarrhea, during study participation.

There are 6 scheduled study visits, including the screening and follow-up visits. The planned duration of participation in this study will be 112 days and up to 155 days, with washout and all visit windows considered. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02122471
Study type Interventional
Source Bausch Health Americas, Inc.
Contact
Status Completed
Phase Phase 3
Start date April 2014
Completion date July 2015

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02361749 - Botulinum Toxin Injection Versus Anal Myectomy in Management of Idiopathic Constipation Phase 4
Terminated NCT02239510 - Efficacy of Linaclotide to Senna for CIC N/A
Completed NCT01895543 - Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation Phase 3
Completed NCT01460225 - Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation Phase 4
Completed NCT02291679 - Trial of Linaclotide in Patients With Chronic Idiopathic Constipation Phase 3
Completed NCT01989234 - A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic Constipation Phase 2
Completed NCT01993875 - Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation Phase 3
Completed NCT01674530 - Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation Phase 3
Completed NCT01429987 - The Plecanatide Chronic Idiopathic Constipation (CIC) Study Phase 2/Phase 3
Completed NCT01982240 - 12-Week Study of Plecanatide for CIC (The CIC3 Study) Phase 3
Completed NCT02590432 - An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation Phase 4
Completed NCT02481947 - A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults Phase 3
Completed NCT01372423 - Evaluation of Clinical Equivalence Between Two Lubiprostone Products Phase 3
Completed NCT03054506 - The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation N/A
Recruiting NCT04804267 - Evaluation of Clinical Equivalence Between Two Linaclotide Products in the Treatment of Chronic Idiopathic Constipation Phase 3
Completed NCT03879239 - Efficacy and Safety of Vibrant Capsule vs. Placebo for the Treatment of Chronic Idiopathic Constipation N/A
Completed NCT01053962 - SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation Phase 2
Completed NCT03097861 - Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo Phase 3
Completed NCT03551873 - A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE®
Completed NCT02819297 - BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults Phase 3